Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
- PMID: 23606961
- PMCID: PMC3628654
- DOI: 10.1155/2013/108401
Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
Abstract
Many laboratories validate DST of the second-line drugs by BACTEC MGIT 960 system. The objective of this study is to evaluate the critical concentration and perform DST for the 2nd line drugs. We evaluated 193 clinical strains of M. tuberculosis isolated from patients in South Korea. Testing the critical concentration of six second-line drugs was performed by MGIT 960 and compared with L-J proportion method. The critical concentration was determined to establish the most one that gave the difference between drug resistance and susceptibility in MGIT960 system. Good agreement of the following concentrations was found: Concordance was 95% for 0.5 μ g/mL of moxifloxacin; 93.6%, 1.0 μ g/mL of levofloxacin; 97.5%, 2.5 μ g/mL of kanamycin; 90.6%, 2.5 μ g/mL of capreomycin; 86.2%, 5.0 μ g/mL of ethionamide; and 90.8%, 2.0 μ g/mL of ρ-aminosalicylic acid. The critical concentrations of the four drugs, moxifloxacin, levofloxacin, kanamycin, and capreomycin, were concordant and reliable for testing 2nd line drug resistance. Further study of ethionamide and ρ -aminosalicylic acid is required.
Similar articles
-
Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System.Int J Tuberc Lung Dis. 2008 Dec;12(12):1449-55. Int J Tuberc Lung Dis. 2008. PMID: 19017456
-
Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex.J Clin Microbiol. 2009 Nov;47(11):3630-4. doi: 10.1128/JCM.00803-09. Epub 2009 Sep 9. J Clin Microbiol. 2009. PMID: 19741086 Free PMC article.
-
Multicenter research on the BACTEC MGIT 960 system for the second-line drugs susceptibility testing of Mycobacterium tuberculosis in China.Diagn Microbiol Infect Dis. 2013 Dec;77(4):330-4. doi: 10.1016/j.diagmicrobio.2013.08.028. Epub 2013 Oct 3. Diagn Microbiol Infect Dis. 2013. PMID: 24091105
-
Evaluation of the BACTEC MGIT 960 SL DST Kit and the GenoType MTBDRsl Test for Detecting Extensively Drug-resistant Tuberculosis Cases.Eurasian J Med. 2017 Oct;49(3):183-187. doi: 10.5152/eurasianjmed.2017.17040. Eurasian J Med. 2017. PMID: 29123441 Free PMC article.
-
GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs.Cochrane Database Syst Rev. 2016 Sep 8;9(9):CD010705. doi: 10.1002/14651858.CD010705.pub3. Cochrane Database Syst Rev. 2016. PMID: 27605387 Free PMC article. Review.
Cited by
-
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.PLoS One. 2023 Oct 26;18(10):e0293194. doi: 10.1371/journal.pone.0293194. eCollection 2023. PLoS One. 2023. PMID: 37883448 Free PMC article.
-
Direct Molecular Detection of Drug-Resistant Tuberculosis from Transported Bio-Safe Dried Sputum on Filter-Paper.Curr Microbiol. 2022 Feb 17;79(4):110. doi: 10.1007/s00284-022-02780-1. Curr Microbiol. 2022. PMID: 35175411
-
A systematic follow-up of Mycobacterium tuberculosis drug-resistance and associated genotypic lineages in the French Departments of the Americas over a seventeen-year period.Biomed Res Int. 2014;2014:689852. doi: 10.1155/2014/689852. Epub 2014 Mar 13. Biomed Res Int. 2014. PMID: 24738068 Free PMC article.
-
Emergence and clonal transmission of multi-drug-resistant tuberculosis among patients in Chad.BMC Infect Dis. 2017 Aug 22;17(1):579. doi: 10.1186/s12879-017-2671-7. BMC Infect Dis. 2017. PMID: 28830384 Free PMC article.
-
Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging.Respirology. 2014 Apr;19(3):448-60. doi: 10.1111/resp.12250. Epub 2014 Feb 21. Respirology. 2014. PMID: 24708034 Free PMC article. Review. No abstract available.
References
-
- Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368(9553):2142–2154. - PubMed
-
- Banerjee R, Schecter GF, Flood J, Porco TC. Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Review of Anti-Infective Therapy. 2008;6(5):713–724. - PubMed
-
- Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575–1580. - PubMed
-
- Raviglione MC, Smith IM. XDR tuberculosis—implications for Global Public Health. New England Journal of Medicine. 2007;356(7):656–659. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials